The Cigna Group

Quarterly Financial Supplement
September 30, 2026

This document is dated November 5, 2026. The data contained in this document may not be accurate after such date and The Cigna Group does not undertake to update or keep it accurate after such date.



The Cigna Group
September 30, 2026 Quarterly Financial Supplement
Table of Contents

Financial Highlights 1
Consolidated Income Statements 2
Evernorth Health Services Segment Analysis 3
Cigna Healthcare Segment Analysis 5
Corporate and Other Operations Analysis 9
Consolidated Balance Sheets 10
Condensed Consolidated Statements of Cash Flows 11

BASIS OF PRESENTATION:

All dollar amounts are in millions, unless otherwise noted.

The Cigna Group® (the "Company" or "our") measures its financial results on a consolidated basis using adjusted income from operations and adjusted revenues. Adjusted income from operations and adjusted revenues on a consolidated basis are not determined in accordance with accounting principles generally accepted in the United States of America ("GAAP") and should not be viewed as a substitute for the most directly comparable GAAP measures which are shareholders' net income and total revenues. The Company also uses adjusted income (loss) from operations to measure the results of its segments, however the segment metric is determined before income taxes.

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations of the Company's businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders' net income. The Company defines adjusted income (loss) from operations as shareholders' net income (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the Financial Highlights page for a reconciliation of consolidated adjusted income from operations to shareholders' net income.

Adjusted revenues is used by The Cigna Group's management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the Financial Highlights page for a reconciliation of consolidated adjusted revenues to total revenues.

In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

In some financial tables in this Quarterly Financial Supplement, we present percentage changes. When those changes are so large as to become not meaningful, we present "N/M" in place of the computed percentage.

The Cigna Group
Financial Highlights (unaudited)

(Dollars in millions, except per share amounts)	Three Months Ended September 30,			Nine Months Ended September 30,		
	2026	2025	% Change	2026	2025	% Change
Total revenues	$ 73,683	$ 69,748	6 %	$ 213,845	$ 202,428	6 %
Net investment results from certain equity method investments	110	(178)	N/M	23	(272)	N/M
Adjusted revenues	$ 73,793	$ 69,570	6 %	$ 213,868	$ 202,156	6 %
Shareholders' net income	$ 1,442	$ 1,868	(23) %	$ 4,756	$ 4,723	1 %
Pre-Tax Adjusted Income (Loss) From Operations by Segment						
Evernorth Health Services	$ 1,829	$ 1,903	(4) %	$ 4,958	$ 5,033	(1) %
Cigna Healthcare	1,193	1,038	15	3,983	3,419	16
Corporate and Other Operations	(372)	(363)	2	(1,138)	(1,131)	1
Adjusted income tax expense	(546)	(482)	13	(1,587)	(1,455)	9
Consolidated after-tax adjusted income from operations	$ 2,104	$ 2,096	— %	$ 6,216	$ 5,866	6 %
Adjusted EBITDA [1]	$ 3,281	$ 3,205	2 %	$ 9,673	$ 9,159	6 %
Operating cash flow (see page 11)	$ 2,571	$ 3,418	(25) %	$ 3,281	$ 3,452	(5) %
SG&A expense ratio [2]	4.9 %	4.8 %	10 bps	5.1 %	5.4 %	(30) bps
Adjusted SG&A expense ratio [2]	4.7 %	4.6 %	10 bps	4.7 %	5.1 %	(40) bps
Weighted average shares (in thousands)	263,788	267,530		263,923	269,527	

	Three Months Ended September 30,					Nine Months Ended September 30,				
	2026		2025			2026		2025		
	Pre-tax	After-tax	Pre-tax	After-tax	% Change	Pre-tax	After-tax	Pre-tax	After-tax	% Change
Diluted earnings per share										
Shareholders' net income		$ 5.47		$ 6.98	(22) %		$ 18.02		$ 17.52	3 %
Adjustments to reconcile to adjusted income from operations										
Net investment losses (gains) [3]	$ 0.28	0.25	$ (0.76)	(0.16)		$ (0.77)	(0.84)	$ (1.29)	(0.72)	
Amortization of acquired intangible assets	2.23	1.71	1.63	1.24		5.19	4.02	4.74	3.70	
Special items										
Strategic optimization program	0.32	0.24	0.82	0.63		2.02	1.53	2.10	1.59	
Charges (benefits) associated with litigation matters	0.23	0.18	(0.06)	(0.05)		0.48	0.38	(0.06)	(0.05)	
Integration and transaction-related costs	0.09	0.06	0.03	0.02		0.35	0.27	1.10	0.84	
Deferred tax expenses, net	—	0.07	—	0.07		—	0.19	—	0.20	
(Gain) on sale of businesses	—	—	(0.14)	(0.90)		(0.02)	(0.02)	(0.29)	(1.32)	
Total special items	$ 0.64	0.55	$ 0.65	(0.23)		$ 2.83	2.35	$ 2.85	1.26	
Adjusted income from operations		$ 7.98		$ 7.83	2 %		$ 23.55		$ 21.76	8 %

CUSTOMER RELATIONSHIPS	As of September 30,			As of December 31,	
(Relationships and lives in thousands)	2026	2025	% Change	2025	% Change
Pharmacy	117,698	122,486	(4) %	123,603	(5) %
Medical (see page 7)	18,452	18,059	2	18,118	2
Behavioral Care	23,012	23,526	(2)	28,269	(19)
Dental	18,400	18,419	—	18,438	—
Total customer relationships	177,562	182,490	(3) %	188,428	(6) %

(1) Adjusted income from operations excluding interest, taxes, depreciation and amortization ("Adjusted EBITDA") is a non-GAAP measure, defined as shareholders' net income excluding income taxes and the pre-tax impact of special items, interest expense, total depreciation and amortization, and net investment results.

(2) SG&A expense ratio is calculated as selling, general and administrative expenses including special items divided by total revenues. Adjusted SG&A expense ratio is calculated as selling, general and administrative expenses excluding special items divided by adjusted revenues.

(3) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

The Cigna Group
Consolidated Income Statements (unaudited)

(Dollars in millions)	Three Months Ended September 30,			Nine Months Ended September 30,		
	2026	2025	% Change	2026	2025	% Change
Revenues						
Pharmacy revenues	$ 58,982	$ 56,054	5 %	$ 170,191	$ 158,336	7 %
Premiums	9,885	9,081	9	29,556	30,973	(5)
Fees and other revenues	4,529	4,380	3	13,337	12,412	7
Net investment income	287	233	23	761	707	8
Total revenues	73,683	69,748	6	213,845	202,428	6
Benefits and expenses						
Pharmacy and other service costs	58,590	55,530	6	169,393	157,196	8
Medical costs and other benefit expenses	8,496	7,842	8	24,850	26,089	(5)
Selling, general and administrative expenses excluding special items	3,443	3,191	8	10,054	10,261	(2)
Amortization of acquired intangible assets	589	436	35	1,368	1,280	7
Special items	169	171	(1)	750	747	—
Total benefits and expenses	71,287	67,170	6	206,415	195,573	6
Income from operations	2,396	2,578	(7)	7,430	6,855	8
Interest expense and other	(333)	(347)	(4)	(1,046)	(1,046)	—
Gain on sale of businesses	—	38	N/M	17	79	(78)
Net investment gains	36	26	38	225	76	196
Income before income taxes	2,099	2,295	(9)	6,626	5,964	11
Total income taxes	401	322	25	1,192	950	25
Net income	1,698	1,973	(14)	5,434	5,014	8
Less: Net income attributable to noncontrolling interests	256	105	144	678	291	133
Shareholders' net income	$ 1,442	$ 1,868	(23) %	$ 4,756	$ 4,723	1 %

	Three Months Ended September 30,					Nine Months Ended September 30,				
	2026		2025			2026		2025		
	Pre-tax	After-tax	Pre-tax	After-tax	% Change	Pre-tax	After-tax	Pre-tax	After-tax	% Change
Shareholders' net income		$ 1,442		$ 1,868	(23) %		$ 4,756		$ 4,723	1 %
Adjustments to reconcile to adjusted income from operations										
Net investment losses (gains) [1]	$ 74	67	$ (204)	(43)		$ (202)	(221)	$ (348)	(194)	
Amortization of acquired intangible assets	589	449	436	332		1,368	1,060	1,280	998	
Special items										
Strategic optimization program	85	62	222	168		535	405	566	429	
Charges (benefits) associated with litigation matters	60	49	(17)	(13)		126	101	(17)	(13)	
Integration and transaction-related costs	23	17	7	6		92	70	297	226	
Deferred tax expenses, net	—	18	—	19		—	51	—	53	
(Gain) on sale of businesses	—	—	(38)	(241)		(6)	(6)	(79)	(356)	
Adjusted income from operations		$ 2,104		$ 2,096	— %		$ 6,216		$ 5,866	6 %

(1) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

The Cigna Group
Evernorth Health Services
Segment Results (unaudited)

(Dollars in millions)	Three Months Ended September 30,			Nine Months Ended September 30,		
	2026	2025	% Change	2026	2025	% Change
Revenues						
Pharmacy revenues	$ 59,366	$ 56,441	5 %	$ 171,150	$ 160,656	7 %
Fees and other revenues	4,382	3,921	12	12,464	11,150	12
Net investment income	26	29	(10)	70	91	(23)
Total revenues [1]	63,774	60,391	6	183,684	171,897	7
Benefits and expenses						
Pharmacy and other service costs	60,519	57,326	6	174,750	163,386	7
Selling, general and administrative expenses [2]	1,147	1,037	11	3,240	3,135	3
Amortization of acquired intangible assets	587	431	36	1,362	1,262	8
Special items	8	15	(47)	19	83	(77)
Total benefits and expenses	62,261	58,809	6	179,371	167,866	7
Income from operations	1,513	1,582	(4)	4,313	4,031	7
Interest expense and other	1	(2)	N/M	—	(1)	N/M
Gain on sale of businesses	—	—	N/M	—	4	N/M
Net investment gains (losses)	94	(17)	N/M	279	67	N/M
Income before income taxes	1,608	1,563	3	4,592	4,101	12
Pre-tax adjustments required to reconcile to adjusted income from operations						
Pre-tax (income) attributable to noncontrolling interests	(280)	(123)		(736)	(342)	
Net investment (gains) losses	(94)	17		(279)	(67)	
Amortization of acquired intangible assets	587	431		1,362	1,262	
Special items	8	15		19	79	
Pre-tax adjusted income from operations	$ 1,829	$ 1,903	(4) %	$ 4,958	$ 5,033	(1) %
Pre-tax margin	2.9 %	3.2 %	(30) bps	2.7 %	2.9 %	(20) bps

(1) Total revenues equal adjusted revenues as there were no special items in the periods presented.

(2) Selling, general and administrative expenses reflect the expenses included in the evaluation of Evernorth Health Services' performance.

The Cigna Group
Evernorth Health Services
Selected Financial Information (unaudited)

(Dollars and pharmacy scripts in millions)	Three Months Ended September 30,			Nine Months Ended September 30,		
	2026	2025	% Change	2026	2025	% Change
Total adjusted revenues						
Pharmacy Benefit Services [1]	$ 37,276	$ 34,091	9 %	$ 104,774	$ 95,787	9 %
Specialty and Care Services [1]	26,498	26,300	1	78,910	76,110	4
Total adjusted revenues	$ 63,774	$ 60,391	6 %	$ 183,684	$ 171,897	7 %
Pre-tax adjusted income from operations						
Pharmacy Benefit Services [1]	$ 765	$ 975	(22) %	$ 1,768	$ 2,352	(25) %
Specialty and Care Services [1]	1,064	928	15	3,190	2,681	19
Total pre-tax adjusted income from operations	$ 1,829	$ 1,903	(4) %	$ 4,958	$ 5,033	(1) %
Pharmacy claim volume [2]	546	558	(2) %	1,610	1,645	(2) %

(1) Includes Net investment income of $7 million and $13 million for Pharmacy Benefit Services and $19 million and $16 million for Specialty and Care Services for the three months ended September 30, 2026 and 2025, respectively, and $16 million and $46 million for Pharmacy Benefit Services and $54 million and $45 million for Specialty and Care Services for the nine months ended September 30, 2026 and 2025, respectively.

(2) Non-specialty network prescriptions filled through 90-day programs and home delivery prescriptions are counted as three claims. All other network and specialty prescriptions are counted as one claim.

The Cigna Group
Cigna Healthcare
Segment Results (unaudited)

(Dollars in millions)	Three Months Ended September 30,			Nine Months Ended September 30,		
	2026	2025	% Change	2026	2025	% Change
Revenues						
Premiums	$ 9,684	$ 8,936	8 %	$ 28,945	$ 30,556	(5) %
Fees and other revenues	1,735	1,881	(8)	5,488	5,331	3
Net investment income	179	116	54	457	376	22
Total revenues	11,598	10,933	6	34,890	36,263	(4)
Benefits and expenses						
Medical costs	8,228	7,579	9	24,053	25,446	(5)
Selling, general and administrative expenses [(1)]	2,290	2,140	7	6,884	7,132	(3)
Amortization of acquired intangible assets	2	5	(60)	6	18	(67)
Special items	76	(13)	N/M	177	(3)	N/M
Total benefits and expenses	10,596	9,711	9	31,120	32,593	(5)
Income from operations	1,002	1,222	(18)	3,770	3,670	3
Interest expense and other	3	2	50	7	6	17
Gain on sale of businesses	—	38	N/M	6	75	(92)
Net investment (losses) gains	(59)	40	N/M	(48)	13	N/M
Income before income taxes	946	1,302	(27)	3,735	3,764	(1)
Pre-tax adjustments required to reconcile to adjusted income from operations						
Net investment losses (gains) [(2)]	169	(218)		71	(285)	
Amortization of acquired intangible assets	2	5		6	18	
Special items	76	(51)		171	(78)	
Pre-tax adjusted income from operations	$ 1,193	$ 1,038	15 %	$ 3,983	$ 3,419	16 %
Pre-tax margin	10.2 %	9.7 %	50 bps	11.4 %	9.5 %	190 bps
Reconciliation of total revenues to adjusted revenues						
Total revenues	$ 11,598	$ 10,933	6 %	$ 34,890	$ 36,263	(4) %
Net investment results from certain equity method investments	110	(178)	N/M	23	(272)	N/M
Adjusted revenues	$ 11,708	$ 10,755	9 %	$ 34,913	$ 35,991	(3) %

(1) Selling, general and administrative expenses reflect the expenses included in the assessment of Cigna Healthcare's performance.

(2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

The Cigna Group
Cigna Healthcare
Premium Revenue and Medical Care Ratio (unaudited)

(Dollars in millions)	Three Months Ended September 30,			Nine Months Ended September 30,		
	2026	2025	% Change	2026	2025	% Change
Premiums:						
U.S. Healthcare						
Employer insured	$ 5,018	$ 4,705	7 %	$ 15,003	$ 14,077	7 %
Stop loss	2,191	1,908	15	6,445	5,655	14
Individual and Family Plans	796	788	1	2,529	2,588	(2)
Other	521	488	7	1,553	1,407	10
U.S. Healthcare - ongoing businesses	8,526	7,889	8	25,530	23,727	8
Medicare Advantage [(1)]	—	—	N/M	—	2,363	N/M
Other [(1)]	—	—	N/M	—	1,415	N/M
U.S. Healthcare - divested businesses [(1)]	—	—	N/M	—	3,778	N/M
Total U.S. Healthcare	8,526	7,889	8	25,530	27,505	(7)
International Health	1,158	1,047	11	3,415	3,051	12
Total premiums	$ 9,684	$ 8,936	8 %	$ 28,945	$ 30,556	(5) %
Medical Care Ratio	85.0 %	84.8 %	20 bps	83.1 %	83.3 %	(20) bps

(1) On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses (the "HCSC transaction"). For additional information, please refer to the Divestiture footnote in the Company's Form 10-K for the period ended December 31, 2025.

The Cigna Group
Cigna Healthcare
Total Medical Customers (unaudited)

MEDICAL CUSTOMERS [1] BY FUNDING TYPE:	As of September 30, 2026	As of September 30, 2025 [5]	% Change	As of December 31, 2025	% Change
(Lives in thousands)					
U.S. Healthcare insured					
Employer insured	2,103	2,175	(3) %	2,179	(3) %
Individual and Family Plans [2]	306	387	(21)	369	(17)
Total U.S. Healthcare insured	2,409	2,562	(6)	2,548	(5)
International Health insured [3]	1,280	1,268	1	1,260	2
U.S. Healthcare administrative services only	14,290	13,790	4	13,875	3
International Health administrative services only [3]	473	439	8	435	9
Total medical customers	18,452	18,059	2 %	18,118	2 %

MEDICAL CUSTOMERS [1] BY MARKET SEGMENT: [4]	As of September 30, 2026	As of September 30, 2025 [5]	% Change	As of December 31, 2025 [5]	% Change
(Lives in thousands)					
U.S. Healthcare					
National Accounts	5,134	5,414	(5) %	5,415	(5) %
Middle Market	7,939	7,402	7	7,460	6
Select	3,319	3,139	6	3,174	5
Small	1	10	(90)	5	(80)
Individual and Family Plans [2]	306	387	(21)	369	(17)
Total U.S. Healthcare	16,699	16,352	2	16,423	2
International Health	1,753	1,707	3	1,695	3
Total medical customers	18,452	18,059	2 %	18,118	2 %

(1) Includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care arrangement or administrative services agreement issued by Cigna Healthcare; (ii) have access to the Cigna Healthcare provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare.

(2) As of September 30, 2026, Individual and Family Plans medical business includes on-exchange Patient Protection and Affordable Care and Education Reconciliation Act ("ACA") business (293 thousand customers) and off-exchange ACA business (13 thousand customers). In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

(3) International Health excludes medical customers served by less than 100% owned subsidiaries, as well as certain customers served by our third-party administrator.

(4) Market Segments are defined as follows:
~ the National Accounts market segment includes employers with 3,000 or more eligible employees;
~ the Middle Market segment includes employers with 500 to 2,999 eligible employees, solutions for third party payers, Taft Hartley plans, and other groups;
~ the Select market segment includes employers with 51 to 499 eligible employees;
~ the Small market segment includes employers with 2 to 50 eligible employees;
~ the Individual and Family Plans market segment offers individual health insurance coverage both on and off the public exchanges;
~ the International Health market segment is focused on health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.

(5) Prior year lives have been reclassified to reflect current market segment presentation according to the definitions discussed in note 4.

The Cigna Group
Cigna Healthcare
Unpaid Claims Liability (unaudited) [1]

(Dollars in millions)	Nine Months Ended September 30,		Year Ended
	2026	2025	December 31, 2025
Beginning balance	$ 4,241	$ 5,018	$ 5,018
Less: Reinsurance and other amounts recoverable	147	159	159
Beginning balance, net	4,094	4,859	4,859
Incurred costs related to:			
Current year	24,409	25,763	33,816
Prior years	(356)	(319)	(342)
Total incurred	24,053	25,444	33,474
Paid costs related to:			
Current year	19,880	20,399	28,769
Prior years	3,412	4,055	4,147
Total paid	23,292	24,454	32,916
Less: Divestiture and other	—	1,323	1,323
Ending balance, net	4,855	4,526	4,094
Add: Reinsurance and other amounts recoverable	133	150	147
Ending balance	$ 4,988	$ 4,676	$ 4,241

(1) Unpaid claims liability is included in the Insurance and contractholder liabilities balance on the Consolidated Balance Sheets, except $983 million classified as liabilities of businesses held for sale as of December 31, 2024. For additional information regarding this liability, see the Insurance and Contractholder Liabilities footnote in the Company's Form 10-Q for the period ended September 30, 2026, expected to be filed on November 5, 2026.

The Cigna Group
Corporate and Other Operations
Results (unaudited)

(Dollars in millions)	Three Months Ended September 30,			Nine Months Ended September 30,		
	2026	2025	% Change	2026	2025	% Change
Revenues						
Total revenues and eliminations [1]	$ (1,689)	$ (1,576)	7 %	$ (4,729)	$ (5,732)	(17) %
Expenses						
Total expenses and eliminations excluding special items [1]	(1,655)	(1,519)	9	(4,630)	(5,553)	(17)
Special items	85	169	(50)	554	667	(17)
Total expenses and eliminations [1]	(1,570)	(1,350)	16	(4,076)	(4,886)	(17)
Loss from operations	(119)	(226)	(47)	(653)	(846)	(23)
Interest expense and other	(337)	(347)	(3)	(1,053)	(1,051)	—
Gain on sale of businesses	—	—	N/M	11	—	N/M
Net investment gains (losses)	1	3	(67)	(6)	(4)	50
Loss before income taxes	(455)	(570)	(20)	(1,701)	(1,901)	(11)
Pre-tax adjustments required to reconcile to adjusted income (loss) from operations						
Net investment (gains) losses	(1)	(3)		6	4	
Special items	84	210		557	766	
Pre-tax adjusted loss from operations	$ (372)	$ (363)	2 %	$ (1,138)	$ (1,131)	1 %

(1) Includes amounts for elimination of intercompany revenues and expenses.

The Cigna Group
Consolidated Balance Sheets (unaudited)

(Dollars in millions)	As of September 30, 2026	As of December 31, 2025		As of September 30, 2026	As of December 31, 2025
Assets			**Liabilities**		
Current Assets			**Current Liabilities**		
Cash and cash equivalents	$ 6,186	$ 7,676	Current insurance and contractholder liabilities	$ 6,404	$ 5,710
Investments	1,109	1,056	Pharmacy and other service costs payable	27,368	30,333
Accounts receivable, net	31,492	28,768	Accounts payable	10,100	10,659
Inventories	5,555	7,338	Accrued expenses and other liabilities	9,868	9,048
Other current assets	2,890	2,976	Short-term debt	2,293	592
Total current assets	47,232	47,814	Total current liabilities	56,033	56,342
Long-term investments	19,043	18,471	Non-current insurance and contractholder liabilities	9,242	9,938
Reinsurance recoverables	3,729	4,103	Deferred tax liabilities, net	6,573	7,145
Property and equipment	3,739	3,651	Other non-current liabilities	5,917	4,238
Goodwill	45,537	44,924	Long-term debt	28,849	30,871
Other intangible assets	26,755	28,560	Separate account liabilities	7,308	7,511
Other assets	4,301	2,885	Total liabilities	113,922	116,045
Separate account assets	7,308	7,511			
			Shareholders' Equity		
			Common stock	4	4
			Additional paid-in capital	32,189	31,790
			Accumulated other comprehensive loss	(4,472)	(2,806)
			Retained earnings	51,385	47,865
			Less: Treasury stock, at cost	(35,723)	(35,140)
			Total shareholders' equity	43,383	41,713
			Noncontrolling interests	339	161
			Total equity	43,722	41,874
Total assets	$ 157,644	$ 157,919	Total liabilities and equity	$ 157,644	$ 157,919

The Cigna Group
Condensed Consolidated Statements of Cash Flows (unaudited)

(Dollars in millions)	Nine Months Ended September 30,	
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	$ 5,434	$ 5,014
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	2,172	2,053
Investment gains, net	(225)	(76)
Deferred income tax benefit	(266)	(174)
Gain on sale of businesses	(17)	(79)
Net changes in assets and liabilities, net of non-operating effects:		
Accounts receivable, net	(2,770)	(6,911)
Inventories	1,782	1,060
Reinsurance recoverable and Other assets	25	(537)
Insurance liabilities	489	1,662
Pharmacy and other service costs payable	(2,964)	1,837
Accounts payable and accrued expenses and other liabilities	(104)	(857)
Other, net	(275)	460
Net cash provided by operating activities	3,281	3,452
Net cash used in investing activities	(2,414)	(3,987)
Net cash used in financing activities	(2,376)	(2,355)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash	(15)	30
Net decrease in cash, cash equivalents and restricted cash	(1,524)	(2,860)
Cash, cash equivalents and restricted cash January 1, [(1)]	7,736	8,931
Cash, cash equivalents and restricted cash September 30, [(2)]	$ 6,212	$ 6,071

(1) Includes restricted cash of $60 million reported in other long-term investments and Other assets as of January 1, 2026.

(2) Includes restricted cash of $26 million reported in other long-term investments and Other assets as of September 30, 2026.